Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Fig. 1

RET alterations in ovarian cancer. a Missense mutations in the CDS (coding sequence) of RET from the TCGA, COSMIC, ICGC and CCLE databases are marked over the affected protein domains. CLD, cadherin-like domain; CRD, cysteine-rich domain; TM, transmembrane domain; TKD, tyrosine kinase domain. b Genes with a mutation frequency ranking in the top 5 of 100 PTKs in ovarian cancer are listed, and the mutation frequency, FDA approved inhibitors and representative reference are also shown. c Kaplan-Meier plot of the progression-free survival of ovarian cancer patients based on RET alterations from the TCGA database

Back to article page